✦ LIBER ✦

Cost-effectiveness of pioglitazone versus acarbose, metformin, and sulphonylureas in the United Kingdom

✍ Scribed by Andrew J Palmer; Christian Weiss; Stephane Roze; Eugen Bumann; Lillian Foerdoes; Arno Brandt; Giatgen A Spinas

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of adding either piog

✍ Andrew J Palmer; Christian Weiss; Stephane Roze; Eugen Bumann; Lillian Foerdoes; 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 147 KB

Long-term effects on lipids and lipoprot

✍ D. J. Betteridge; B. Vergès 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 135 KB

Effect of pioglitazone and acarbose on e

✍ G. Derosa; R. Mereu; A. D’Angelo; S. A. Salvadeo; I. Ferrari; E. Fogari; A. Grav 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 310 KB

Evaluation of the cost-effectiveness of

✍ Phil McEwan; Keshwar Baboolal; Pete Conway; Craig J. Currie 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 874 KB

Cost Effectiveness of Saxagliptin and Me

✍ Wilma Erhardt, Klas Bergenheim, Isabelle Duprat-Lomon, Dr Phil McEwan 📂 Article 📅 2012 🏛 Springer International Publishing AG 🌐 English ⚖ 372 KB

PDB45 Cost-Effectiveness of Vildagliptin

✍ Calado, F.; Gruenberger, J.B.; Silva-nunes, J.; Carvalho, D. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB